학술논문
118E. Efficacy and safety of tedizolid phosphate for 6 days versus linezolid for 10 days in a phase 3 study in patients with ABSSSI using the new FDA primary outcome measure.
Document Type
Academic Journal
Source
Pharmacotherapy: The Journal Of Human Pharmacology And Drug Therapy. Oct 01, 2012 32(10):e212-e212
Subject
Language
English
ISSN
0277-0008